Рет қаралды 4,981
This is a recording of the talk I gave on Wednesday 7th September 2022 at the international Paediatric Inflammatory Bowel Disease (PIBD) meeting at Edinburgh International Conference Centre.
My talk was in a session that contained talks on the immune system, genome and microbiome in IBD. I was talking about the IBD Exposome - which means the environmental factors associated with IBD.
This talk put the IBD Exposome into context, discusses modifiable factors and then a deep dive into dietary factors.
I outline the PREdiCCt Study we are running looking to understand which aspects of the environment, diet, genetics and the microbiome are associated with and predict disease flare in IBD. PREdiCCt has finished follow-up and we are in the process of cleaning and analysing the data.
Video Editing by @IBDNathan Nathan Constantine-Cooke
charlielees.su... ATOMIC IBD
charlielees.com/
www.predicct.c...
/ @charlie_lees
#atomicIBD #crohnsdisease #crohn #IBD #inflammatoryboweldisease #colitis #ulcerativecolitis #UC @crohnsandcolitisuk
PROFESSOR CHARLIE W LEES FRCP(Ed) PhD
Charlie is Professor of Gastroenterology at the University of Edinburgh, a UK Research and Innovation Future Leaders Fellow (UKRIFLF) and Consultant Gastroenterologist in the Edinburgh IBD Unit. His clinical, teaching and research interests have been focused on inflammatory bowel disease (IBD) since 2003. He was awarded his PhD in the Genetics of IBD and the prestigious UEG Rising Star award in Gastroenterology, both in 2009. Following this he spent 10 years working as a full-time consultant gastroenterologist leading an increasingly busy and complex IBD clinic.
In 2019 Charlie was awarded a personal fellowship from UKRI - worth £1.7m - that enabled his transition to full-time academic gastroenterology. His research team are based in the Centre for Genomics and Experimental Medicine within the Institute of Genetics and Cancer in Edinburgh.
Charlie’s core mission is to improve outcomes for people living with IBD.
His team are working on predicting outcomes in IBD, using routinely collected NHS data (the Lothian IBD Registry) and dedicated multi-modal prospective cohorts to build predictive models.
He is Chief Investigator of the PREdiCCt study, which has recruited 2650 patients in clinical remission with detailed baseline phenotyping (clinical, psycho-social, lifestyle, environmental, dietary, microbiome and genomics) and a minimum of 24 months longitudinal follow-up.
Conflicts of Interest
Professor Charlie Lees has acted as a speaker and/or consultant to Abbvie, Janssen, Takeda, Pfizer, Galapagos, GSK, Gilead, Vifor Pharma, Ferring, Dr Falk, BMS, Boehringer Ingelheim, Novartis, Sandoz, Celltrion, Fresnius Kabi, Tillotts, Trellus Health and Iterative Scopes.